Results 21 to 30 of about 35,812 (218)

Potential therapeutic effect of epigenetic therapy on treatment-induced neuroendocrine prostate cancer

Asian Journal of Andrology, 2017
Although adenocarcinomas of the prostate are relatively indolent, some patients with advanced adenocarcinomas show recurrence of treatment-induced neuroendocrine prostate cancer, which is highly aggressive and lethal.
Xiang Xu, Yu-Hua Huang, Yan-Jing Li, Alexa Cohen, Zhen Li, Jill Squires, Wei Zhang, Xu-Feng Chen, Min Zhang, Jiao-Ti Huang   +9 more
doaj   +1 more source

Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation

Frontiers in Oncology, 2022
The development of a neuroendocrine phenotype as a mechanism of resistance to hormonal treatment is observed in up to 20% of advanced prostate cancer patients.
Marco Bergamini, Alberto Dalla Volta, Irene Caramella, Luisa Bercich, Simona Fisogni, Mattia Bertoli, Francesca Valcamonico, Salvatore Grisanti, Pietro Luigi Poliani, Francesco Bertagna, Alfredo Berruti   +10 more
doaj   +1 more source

Clinical features of neuroendocrine prostate cancer [PDF]

European Journal of Cancer, 2019
Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that may arise de novo or in patients previously treated with hormonal therapies for prostate adenocarcinoma as a mechanism of resistance. Despite being important to recognise, the clinical features of NEPC are poorly defined and could help guide when to perform a biopsy ...
Vincenza Conteduca, Clara Oromendia, Kenneth W. Eng, Rohan Bareja, Michael Sigouros, Ana Molina, Bishoy M. Faltas, Andrea Sboner, Juan Miguel Mosquera, Olivier Elemento, David M. Nanus, Scott T. Tagawa, Karla V. Ballman, Himisha Beltran   +13 more
openaire   +3 more sources

Neuroendocrine and Aggressive-Variant Prostate Cancer [PDF]

Cancers, 2020
In prostate cancer, neuroendocrine (NE) differentiation may rarely present de novo or more frequently arises following hormonal therapy in patients with castration-resistant prostate cancer (CRPC). Its distinct phenotype is characterized by an aggressive clinical course, lack of responsiveness to hormonal therapies and poor prognosis.
Spetsieris, Nicholas, Boukovala, Myrto, Patsakis, Georgios, Alafis, Ioannis, Efstathiou, Eleni   +4 more
openaire   +2 more sources

Neuroendocrine differentiation in prostate cancer

Vojnosanitetski pregled, 2004
Background. In numerous recent studies attention has been focused to neuroendocrine differentiation (NED) in prostate cancer (PC). Focal NED is present in almost all PCs, but it is prominent in only 5-10% of the carcinomas. The prognostic significance of focal NED in PC is controversial, but current evidence suggests its influence on the onset and/or ...
Snezana Cerovic, Goran Brajuskovic, Vinka Maletic-Vukotic, Sava Micic   +3 more
openaire   +3 more sources

ONECUT2 is a driver of neuroendocrine prostate cancer [PDF]

Nature Communications, 2019
AbstractNeuroendocrine prostate cancer (NEPC), a lethal form of the disease, is characterized by loss of androgen receptor (AR) signaling during neuroendocrine transdifferentiation, which results in resistance to AR-targeted therapy. Clinically, genomically and epigenetically, NEPC resembles other types of poorly differentiated neuroendocrine tumors ...
Haiyang Guo, Xinpei Ci, Musaddeque Ahmed, Junjie Tony Hua, Fraser Soares, Dong Lin, Loredana Puca, Aram Vosoughi, Hui Xue, Estelle Li, Peiran Su, Sujun Chen, Tran Nguyen, Yi Liang, Yuzhe Zhang, Xin Xu, Jing Xu, Anjali V. Sheahan, Wail Ba-Alawi, Si Zhang, Osman Mahamud, Ravi N. Vellanki, Martin Gleave, Robert G. Bristow, Benjamin Haibe-Kains, John T. Poirier, Charles M. Rudin, Ming-Sound Tsao, Bradly G. Wouters, Ladan Fazli, Felix Y. Feng, Leigh Ellis, Theo van der Kwast, Alejandro Berlin, Marianne Koritzinsky, Paul C. Boutros, Amina Zoubeidi, Himisha Beltran, Yuzhuo Wang, Housheng Hansen He   +39 more
openaire   +6 more sources

Comprehensive analysis of androgen receptor status in prostate cancer with neuroendocrine differentiation

Frontiers in Oncology, 2022
The androgen receptor (AR) signaling is a key contributor to tumorigenesis and the progression of prostate cancer. A subset of patients may develop neuroendocrine (NE) features, resulting in resistance to androgen deprivation therapy and poor prognosis ...
Ruopeng Su, Lei Chen, Zhou Jiang, Minghao Yu, Weiwei Zhang, Zehua Ma, Yiyi Ji, Kai Shen, Zhixiang Xin, Jun Qi, Wei Xue, Qi Wang, Qi Wang   +12 more
doaj   +1 more source

[Neuroendocrine prostate cancer].

Der Urologe. Ausg. A, 2016
Neuroendocrine carcinoma of the prostate (NEPC) is a rare, androgen-independent variant of prostate cancer with increasing incidence of over the past few years. It commonly progresses rapidly and is associated with a poor prognosis. Based on a different tumor biology compared to adenocarcinomas of the prostate, standard therapeutic approaches for ...
A, Kretschmer, C, Wittekind, C G, Stief, C, Gratzke   +3 more
openaire   +3 more sources

Role of MicroRNAs in Neuroendocrine Prostate Cancer

Non-Coding RNA, 2022
Therapy-induced neuroendocrine prostate cancer (t-NEPC/NEPC) is an aggressive variant of prostate cancer (PCa) that frequently emerges in castration-resistant prostate cancer (CRPC) under the selective pressure of androgen receptor (AR)-targeted therapies. This variant is extremely aggressive, metastasizes to visceral organs, tissues, and bones despite
Amritha Sreekumar, Sharanjot Saini
openaire   +3 more sources

Neuroendocrine differentiation in the progression of prostate cancer [PDF]

International Journal of Urology, 2008
AbstractNeuroendocrine (NE) cells originally exist in the normal prostate acini and duct, regulating prostatic growth, differentiation and secretion. Clusters of malignant NE cells are found in most prostate cancer (PCa) cases. NE differentiation (NED) is the basic character of the prostate, either benign or malignant.
Akira, Komiya, Hiroyoshi, Suzuki, Takashi, Imamoto, Naoto, Kamiya, Naoki, Nihei, Yukio, Naya, Tomohiko, Ichikawa, Hideki, Fuse   +7 more
openaire   +2 more sources